Login

|

Register

  • Home

    • Amazon FBA Support

      Amazon handed prep work back to sellers, and the consequences of getting it wrong land on you rather than on them. A carton that arrives wrong gets refused, refused stock sits somewhere earning nothing, and a launch date moves.

      Amazon FBM Support

      FBM keeps the things worth keeping. Your packaging, customer data & margin. It also puts Amazon’s performance metrics directly on your dispatch times, which is a comfortable trade at home and a much harder one from four thousand miles away.

      Direct-to-Consumer Fulfilment

      On a marketplace, a slow delivery is the marketplace’s fault. On your own store it is yours. The box that arrives, the day it arrives and how easy it is to send back are all part of what someone bought, and they decide whether a first order becomes a second one.

      Returns, Reworks & Recycling

      Treated as a cost, a return is written off twice, once on the refund and again on the unit. Treated as inventory, a lot of it goes back on sale. What decides which of those happens is how quickly the unit gets looked at and how far it had to travel to be looked at.

      Warehouse Location

      Stock held inside the market it sells into arrives as a domestic delivery. No customs event on the order, and nothing for your customer to settle before the courier hands the parcel over. Ours sits in the UK, the Netherlands and the US, which covers...

  • Contact Us

Expandly Blog

Ashwagandha Regulation Is Escalating: What Supplement Brands Must Check Now

India’s FSSAI leaf ban, Netherlands’ ban intent, and a European Parliament scientific expert meeting on July 14, 2026 are converging on the same regulatory direction. Supplement brands with EU or UK market ambitions need verified supply chain controls in place.

In This Article

01 Why ashwagandha regulation is escalating
02 Withaferin-A and supply chain contamination risk
03 Active bans and assessments across markets
04 What the July 14 EP meeting determines
05 Actions for brands with EU or UK ambitions

Key Takeaways

► Root-only labeling is insufficient without verified batch testing
► Netherlands ban intent confirmed; effective date not set
► July 14 EP meeting is the key near-term regulatory signal
► EU-wide restriction possible via EFSA and Article 8 CFIA

The regulatory environment for ashwagandha is shifting across multiple markets at once. India restricted leaf-derived ashwagandha in April 2026. The Netherlands confirmed intent to ban it. On July 14, 2026, the European Parliament convenes a scientific expert meeting on ashwagandha safety. It is the most significant near-term signal for whether an EU-wide restriction follows.

July 14, 2026 European Parliament scientific expert meeting on ashwagandha safety. The outcome informs whether EFSA moves toward a formal assessment that could produce an EU-wide restriction via Article 8 CFIA. Source: NutraIngredients, July 2026.

Withaferin-A, a compound present in ashwagandha leaves, has been linked to liver toxicity in scientific review. Root-derived ashwagandha carries a different risk profile, as the concern is specific to leaf material. But supply chain contamination is a documented problem. HPTLC analysis of 584 ashwagandha batches found leaf residue in 14% of samples and incomplete root in 20.4%. A root-only label from a supplier does not guarantee root-only content without verified batch testing documentation.

The regulatory sequence is active across multiple markets. India's FSSAI issued its advisory on April 16, 2026, restricting ashwagandha leaves in any form. Denmark banned ashwagandha in 2020. The Netherlands WVS confirmed intent to ban on April 10, 2026; an effective date has not been set. The UK Food Standards Agency closed its call for evidence in September 2024, with the Committee on Toxicity assessment ongoing. EFSA was mandated in 2024 to conduct a formal safety assessment.

If the July 14 EP expert meeting produces recommendations supporting restriction, the path runs through EFSA formal assessment, then an Article 8 CFIA procedure, and potentially to an EU-wide restriction applying in all member states. National bans in Denmark and Netherlands would become a subset of that broader outcome. France's ANSES and Germany's BfR have both issued warnings for specific populations. The regulatory direction is consistent across jurisdictions.

  • India's FSSAI advisory (April 16, 2026) restricts ashwagandha leaves in any form. Root-derived material only.
  • Netherlands WVS confirmed intent to ban ashwagandha (April 10, 2026). Effective date not yet set.
  • EFSA formal safety assessment mandated in 2024. An EU-wide restriction via Article 8 CFIA could follow.
  • Supply chain verification matters: 14% of tested batches contained leaf residue despite root-only labeling.

For supplement brands entering EU or UK markets, ingredient compliance review is part of Expandly's initial compliance setup. If ashwagandha is in your formulations, root-only sourcing with batch testing documentation is a prerequisite before listing.

Expandly helps US ecommerce brands expand into Europe — compliance, marketplaces and fulfilment, all handled. We’ve supported 2,000+ brands make the move.

Find out more
  • EPR compliance managed from day one — packaging, WEEE, batteries and beyond
  • Product label review and Responsible Person service for EU and UK market entry

The bigger picture

Ashwagandha regulatory escalation and what it signals for EU entry

The ashwagandha story follows a regulatory pattern that applies to multiple EU-monitored ingredients: a national ban creates a demonstration effect, EFSA is mandated to assess, and an Article 8 CFIA procedure can produce a measure applying across all 27 member states. For supplement brands that have built a US product range around adaptogens, this is the clearest current example of why EU market entry requires formulation review before the first shipment arrives. Expandly's compliance setup for health and wellness brands starts with an ingredient review against EU and UK permitted lists, specifically to identify issues like this before they affect market access or trigger a listing removal.

  • EFSA safety assessments are a prerequisite for EU-wide restrictions under Article 8 CFIA; once mandated, the regulatory timeline is running
  • National bans in Denmark and Netherlands apply now; brands with EU distribution or warehouse stock in either market need to confirm compliance status
  • Supply chain verification, not just a root-only label, is required for any brand selling ashwagandha in a regulated EU or UK market

US supplement market demand

43% of US adults use food supplements at least weekly. Supplement brands with an established US customer base are entering EU markets where ingredient regulation is moving faster than most expect.

43%

of US adults use supplements weekly. Source: CRN Consumer Survey, 2025.

EU supplement compliance requirement

Every EU member state requires a Responsible Person designation for food supplements placed on the market under Directive 2002/46/EC. This applies before your product reaches a consumer or marketplace listing.

27

EU member states. Directive 2002/46/EC.

EU Responsible Person, Included

Cosmetics, supplements and electronics sold in the EU require a designated Responsible Person. Expandly provides this designation as part of your compliance setup, with no separate service or third party required.

2,000+

brands expanded with Expandly

If this sounds like your world,
let's talk.

Expandly helps US ecommerce brands expand into Europe — compliance, marketplaces and fulfilment, all handled.

Self-Serve

  • £1,150/month
  • Platform-led with email support
  • Best for: $1M–$5M brands

Guided

  • £3,000/month
  • Dedicated Account Manager
  • Best for: $5M–$20M brands

VIP

  • £5,000/month
  • Dedicated VIP Consultant
  • Best for: $20M–$50M+ brands
See full pricing and what's included